SEC Form 4 · accession 0001209191-18-025586
Ultragenyx Pharmaceutical Inc. · RARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Emil D Kakkis
Officer — President & CEO · Director
Period of report
Apr 19, 2018
Accepted (ET)
Apr 19, 2018 · 4:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001515673
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Apr 19, 2018 | A | 3,429 | $0.00 | A | 452,384 | D | |
| Common Stock | holding | — | — | — | 2,559,741 | I | By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on April 19, 2018 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date.
- F2Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.